Q-omics provides the consensus-scored ZNF384 profile across patient tissues and cancer cell-line models. ZNF384 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZNF384 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZNF384 RNA expression shows 20,273 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, KIRC, and THYM as cancer lineages where ZNF384 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF384 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF384 survival associations across molecular data types. ZNF384 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF384 RNA expression–survival associations across cancer types. High ZNF384 expression shows unfavorable associations in COAD and ACC, but favorable associations in SCLC, KIRC, HNSC and UCEC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for ZNF384 RNA expression.
This table summarizes ZNF384 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF384. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF384 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, LIHC, COAD and BLCA. The KIRC box plot shows higher ZNF384 RNA expression in tumor versus normal tissue (log2 FC = +0.644, t-test p < 0.001).
This table shows molecular features associated with ZNF384 in patient tissues and cancer cell lines. In patient samples, ZNF384 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF384 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
